- CRS Publications
- News
News
Authors:
Date:
Business Wire: October 24, 2016 – STOCKHOLM, Sweden – Braeburn Pharmaceuticals and Camurus (STO: CAMX) today announced the expansion of their collaboration and license agreement from 2014 to include buprenorphine combination products. The first drug candidate within the expanded scope (CAM2058) is…
Authors:
Date:
Business Wire: October 13, 2016 – BEDFORD, MA, U.S.A. – Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a strategic…
Authors:
Date:
PRNewswire: October 10, 2016 – PHILADELPHIA, PA, U.S.A. – Biopharmaceuticals like insulin have been used for decades in medical practice, but dental medicine has few such drugs and those that are used are delivered invasively, often through gum surgery.
Now, a report in Biomaterials by Penn Dental…
Authors:
Date:
PRNewswire: October 6, 2016 – WARREN, NJ, U.S.A., BALTIMORE, MD, U.S.A., and MUMBAI, India – Lupin Pharmaceutical Inc., the U.S. subsidiary of pharma major Lupin Limited (collectively Lupin), and MonoSol Rx, a specialty pharmaceutical company, have entered into a strategic licensing agreement…
Authors:
Date:
Business Wire: October 3, 2016 – MIAMI, FL and NEW YORK, NY, U.S.A. – Noven Pharmaceuticals, Inc., today announced the appointment of Ralph Lipp, Ph.D., as the company’s new vice president and chief scientific officer. In this role, Dr. Lipp will lead all research and development efforts for Noven’…
Authors:
Date:
Business Wire: September 26, 2016 – CAMBRIDGE, MA, U.S.A. – Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the company will focus its resources on its proprietary GalXC™ technology platform to advance…
